FDA allows emergency use of COVID pill molnupiravir | Inquirer News
Close  
ONLY FOR PATIENTS WITH MILD TOMODERATE SYMPTOMS

FDA allows emergency use of COVID pill molnupiravir

/ 05:42 AM December 24, 2021

FOR 18 AND ABOVE The country’s health regulatory agency approved the wider use of the COVID-19 treatment pill called molnupiravir, which was previously available only in select health facilities. —Reuters

The country’s health regulatory agency has allowed the emergency use of the COVID-19 treatment pill molnupiravir.

The Food and Drug Administration (FDA) granted the application for emergency use authorization (EUA) of Molnarz’s molnupiravir, a licensee of pharmaceutical company MSD or Merck & Co.

ADVERTISEMENT

The EUA allows wider use of molnupiravir on people infected with the coronavirus. Previously, under a compassionate use permit, it could be used only in select health facilities. According to FDA Director General Eric Domingo, the molnupiravir pill comes in 200-milligram capsules and can be given to patients with mild and moderate COVID-19.

Limited users

At Thursday’s Laging Handa briefing, Domingo said the pill could be given only to adults 18 years old and above who were found positive for COVID-19 and with risk factors for developing severe illness, such as senior citizens and those with comorbidities.

FEATURED STORIES

He said it could not be given to those with severe symptoms or those with low oxygen level, as well as pregnant and lactating women.

“We do not have enough data to say that it would be safe for this group of patients,” Domingo said.

Molnupiravir would be given in dosages of 800 mg twice a day for five days.

Patients must take the drug as soon as possible after diagnosis, and within the first five days after the onset of symptoms or “it would not be very useful,” he said.

“It can’t be given to patients with severe illness because it would not help,” Domingo added.

In November, Merck said the molnupiravir pill, which it developed with Ridgeback Biotherapeutics, showed a 30-percent reduction in hospitalizations and deaths, lower than the 50-percent efficacy indicated by earlier data.

The updated data, Merck said, came from a study involving 1,433 COVID-19 patients.

ADVERTISEMENT

In October, Merck said its data showed a 50-percent efficacy, based on data from 775 patients.

In the same month, the Philippine FDA granted several hospitals a compassionate special permit for the use of molnupiravir.

A five-day molnupiravir treatment reportedly costs about $700 in the United States.

The antiviral medication introduces “copying errors” into the genetic code of the virus during RNA replication, making the virus harmless. This prevents the deadly growth and spread of COVID-19 in the body. —with a report from Inquirer Research

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link .

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: COVID-19, covid-19 pill, FDA, molnupiravir
For feedback, complaints, or inquiries, contact us.

News that matters

By providing an email address. I agree to the Terms of Use and
acknowledge that I have read the Privacy Policy.



© Copyright 1997-2022 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.